AVAILABLE MEDICINE FOR Cycloserine
There are no products to list.
Introduction to Cycloserine
Cycloserine is an antibiotic distinguished by its unique mechanism of action, primarily aimed at treating multidrug-resistant tuberculosis (MDR-TB). Acting as a structural analogue of D-alanine, it disrupts the synthesis of bacterial cell walls by inhibiting the enzymes that facilitate peptidoglycan formation, which is crucial for maintaining the integrity of bacterial cells. Its effective tissue penetration makes Cycloserine a valuable option for addressing infections resistant to standard first-line antitubercular medications. It proves particularly useful when traditional therapies are ineffective, providing a critical alternative for managing challenging tuberculosis cases. Typically taken orally, the dosage of Cycloserine is meticulously tailored to the severity of the infection and how well the patient responds. Although it is generally well-tolerated, some potential side effects may arise, particularly affecting the central nervous system (CNS), such as dizziness, headaches, and seizures at elevated doses. Therefore, careful monitoring and adjustments to dosage are necessary to reduce these adverse effects.
The FDA approved Cycloserine in the 1950s specifically for tuberculosis treatment due to its significance in combating drug-resistant strains. However, because of its potential serious CNS side effects, it is usually reserved for particular situations and used alongside other antitubercular drugs. Ongoing research underscores Cycloserine's essential role in tackling MDR-TB and highlights the necessity for effective treatments against drug-resistant infections to enhance patient outcomes in tuberculosis care.
